PvP Biologics Acquired By Takeda
Following the conclusion of a Phase I proof-of-mechanism study of its investigational medicine TAK-062, Takeda has announced its acquisition of PvP Biologics. TAK-062 is meant to be used for providing the treatment of uncontrolled celiac disease. This is highly potent…